The role of tafasitamab in the lymphoma treatment landscape & promising results from clinical trials

The role of tafasitamab in the lymphoma treatment landscape & promising results from clinical trialsПодробнее

Real-world efficacy of tafasitamab + lenalidomide in R/R DLBCL & the importance of patient selectionПодробнее

Long-term follow-up of tafasitamab and lenalidomide in R/R DLBCLПодробнее

An insight into how bispecifics are changing the lymphoma treatment landscapeПодробнее

The latest updates on tafasitamab in DLBCLПодробнее

First-MIND: Phase Ib study of R-CHOP + tafasitamab ± lenalidomide in newly diagnosed DLCBLПодробнее

Tafasitamab Plus Lenalidomide Approval Generates Excitement for Second-Line DLBCLПодробнее

Advancements in the DLBCL treatment landscapeПодробнее

Tafasitamab-lenalidomide in R/R DLBCL: clinical trial results and real-world dataПодробнее

The use of tafasitamab and lenalidomide in R/R DLBCLПодробнее

The impact of tafasitamab on the efficacy and safety of CD19 CAR-T therapy in preclinical modelsПодробнее

The evolving treatment landscape of R/R LBCLПодробнее

Dr. Kahl on Findings From the L-MIND Study With Tafasitamab in DLBCLПодробнее

The use of tafasitamab in DLBCLПодробнее

The role of novel therapies in R/R DLBCLПодробнее

frontMIND: tafasitamab + lenalidomide + R-CHOP vs R-CHOP in newly diagnosed high-risk DLBCLПодробнее

RE-MIND2: observational study comparing tafasitamab+lenalidomide to available therapies in R/R DLBCLПодробнее

Tafasitamab at the blood-brain barrier: exploring this agent for the treatment of CNS lymphomaПодробнее

FrontMIND: tafasitamab + lenalidomide + R-CHOP vs R-CHOP for newly diagnosed high-risk DLBCLПодробнее

L-MIND Trial in Relapsed/Refractory DLBCLПодробнее